Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill aims to ease social anxiety in clinical trial

NCT ID NCT07193563

Symptom relief Sponsor: Engrail Therapeutics INC Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental drug called ENX-102 in 47 adults with social anxiety disorder. Participants received either the drug or a placebo to see if it reduced fear and avoidance in social situations. The goal was to measure safety and how well the drug works as a standalone treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

47 people

The number who actually took part.

Started

Sep 2025

Finished

Mar 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Male or female at birth, aged 18-70 years, inclusive, at screening Diagnosed with SAD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), confirmed by a Mini-International Neuropsychiatric Interview (MINI) version 7.0.2 * LSAS total score of ≥70 * CGI-S score of ≥4 Key Exclusion Criteria: * Clinically predominant psychiatric diagnosis other than SAD per the MINI * Any past/lifetime or current diagnosis of a neurocognitive disorder or psychotic disorder, or any current diagnosis of posttraumatic stress disorder, obsessive compulsive disorder, or bipolar disorder * Reports moderately severe to severe symptoms of depression * Frequent use of benzodiazepines within 90 days of screening * Used prohibited medication or prohibited herbal or other supplements within 5 half- lives or 21 days prior to Day 1 and unwillingness to refrain from their use for the duration of the trial * Recent suicidal ideation or behavior * Current or recent moderate or severe substance use disorder as assessed by the MINI * Is unwilling/unable to abstain from alcohol, marijuana, THC, CBD, and/or any other psychoactive substances (except for nicotine or caffeine) for the duration of the trial, per Investigator judgment, and/or has a positive alcohol test or drug test at Screening or Day 1 * Clinically significant abnormal findings in safety assessments * Has significant progressive disorders or unstable medical conditions Unable to comply with the requirements of the study or, in the opinion of the Investigator or Sponsor, is unsuitable for the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Social anxiety disorder (SAD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

social phobia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Social anxiety disorder (SAD)

Contacts and locations

Locations

  • Anderson Clinical Research

    Redlands, California, 92374, United States

  • Austin Clinical Trials Partners

    Austin, Texas, 78737, United States

  • CNS Health

    Jacksonville, Florida, 32256, United States

  • California Neuroscience Research, LLC

    Sherman Oaks, California, 91403, United States

  • CenExel iResearch, LLC

    Savannah, Georgia, 31405, United States

  • Cenexel HRI

    Berlin, New Jersey, 08009, United States

  • Clinical Neuroscience Solutions, Inc.

    Orlando, Florida, 32801, United States

  • Clinical Neurosciences, Inc

    Memphis, Tennessee, 38119, United States

  • Core Clinical Research

    Everett, Washington, 98201, United States

  • Excell Research, Inc.

    Oceanside, California, 92056, United States

  • Grayline Research Center

    Wichita Falls, Texas, 76309, United States

  • IMA Clinical Research

    Las Vegas, Nevada, 89102, United States

  • IMA Clinical Research Phoenix

    Phoenix, Arizona, 85012, United States

  • Mountain View Clinical Research

    Denver, Colorado, 80209, United States

  • Neurobehavioral Research, Inc.

    Cedarhurst, New York, 11516, United States

  • Neuroresearch Group

    Los Angeles, California, 90025, United States

  • Redbird Research

    Las Vegas, Nevada, 89119, United States

  • SPRI Clinical Trials, LLC

    Brooklyn, New York, 11235, United States

  • Sunwise Clincial Research

    Walnut Creek, California, 94596, United States

  • University of California

    La Jolla, California, 92037, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.